Charleston Laboratories has ended its Phase III trial of CL-108 at the midway point. An independent Data Monitoring Committee reviewed the safety and efficacy results in an interim analysis and notified Charleston Labs that the study should be stopped because both efficacy endpoints of the study have been met. CL-108 is a strong pain reliever designed to also prevent nausea and vomiting. The recommendation was based on the demonstration of the safety of CL-108, the significant effect on opioid-...